Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Flublok

Vaccine (Recombinant protein vaccine) · Immune activation, directed at Influenza A virus hemagglutinin and Influenza B virus hemagglutinin · developed by Protein Sciences

Approved FDA, Jan 2013
1 Registered trials

What is Flublok?

Flublok is a quadrivalent influenza vaccine containing recombinant hemagglutinin antigens from influenza A and B viruses. It is administered to prevent seasonal influenza infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Recombinant protein vaccine)
Targets
Influenza A virus hemagglutinin (antigen), Influenza B virus hemagglutinin (antigen)
Mechanism
Immune activation, directed at Influenza A virus hemagglutinin and Influenza B virus hemagglutinin
Pathways
immune_activation
Therapy area
Infectious disease
Developer
Protein Sciences Corporation
In trials of
NVAX
FDA status
Approved (January 16, 2013), BLA125285

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03658629 Phase 2 Influenza, Human Terminated NVAX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Influenza, Human

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.